Tempus AI, Inc.

TEM · Nasdaq · ·

비교

US$79.41-1.4%11월 11일 종가

2026년 9월 30일까지의 수치 (2026년 11월 2일 제출 10-Q 기준)

1W: +4.4%
1M: +16.4%
3M

Tempus AI, Inc. (TEM) 주식 — 좋은 사업일까? — InspectStocks

Tempus AI, Inc.

TEM · Nasdaq · ·

비교

US$79.41-1.4%11월 11일 종가

2026년 9월 30일까지의 수치 (2026년 11월 2일 제출 10-Q 기준)

1W: +4.4%
1M: +16.4%
3M

Just reported

Q3 2026 results

From Tempus AI's results release of 2026년 11월 2일; its quarterly report has since been filed.

Revenue
Actual
US$411.5M
+23% y/y
+7.6% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-US$0.08
Guided
—
No guide given
Operating income, GAAP
Actual
-US$56.9M
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$1.6B – US$1.605B+26% y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Health Information Services

Graded A or B and worth $2B or more: A first, then the largest.

All 41 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Diagnostic testing75%
Data and applications25%

매출 비중은 nine months ended September 30, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.

3개 더 보기

Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.

누가 사는가4

Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
Drug companies pay for help identifying patients who may qualify for clinical trials.
Academic research institutions buy laboratory testing and related research services.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.

잘못될 수 있는 일

1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.

전체 재무제표 보기 →

Tempus AI, Inc. 소개

Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.

본사: Chicago, Illinois
설립: 2015
상장 시장: Nasdaq
회계연도 종료: December 31

Tempus AI, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported